Navidea Biopharma (NAVB) Reports In-Line Q4 EPS

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $2.1 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• SanDisk upgraded at JPMorgan after investor day; shares climb
• Star Equity to acquire Harte Hanks for $5 per share in cash and stock
• Reading (RDI) Tops Q2 EPS by 4c